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α-melanocyte stimulating hormone treatment in 
pigs does not improve early graft function in kidney 
transplants from brain dead donors 
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Delayed graft function and primary non-function are serious complications following 
transplantation of kidneys derived from deceased brain dead (DBD) donors. 
α-melanocyte stimulating hormone (α-MSH) is a pleiotropic neuropeptide and its 
renoprotective effects have been demonstrated in models of acute kidney injury. We 
hypothesized that α-MSH treatment of the recipient improves early graft function and 
reduces inflammation following DBD kidney transplantation. 
Eight Danish landrace pigs served as DBD donors. After four hours of brain death both 
kidneys were removed and stored for 18 hours at 4°C in Custodiol® preservation 
solution. Sixteen recipients were randomized in a paired design into two treatment 
groups, transplanted simultaneously. α-MSH or a vehicle was administered at start 
of surgery, during reperfusion and two hours post-reperfusion. The recipients were 
observed for ten hours following reperfusion. Blood, urine and kidney tissue samples 
were collected during and at the end of follow-up.
α-MSH treatment reduced urine flow and impaired recovery of glomerular filtration rate 
(GFR) compared to controls. After each dose of α-MSH, a trend towards reduced mean 
arterial blood pressure and increased heart rate was observed. α-MSH did not affect 
expression of inflammatory markers.
Surprisingly, α-MSH impaired recovery of renal function in the first ten hours following 
DBD kidney transplantation possibly due to hemodynamic changes. Thus, in a porcine 
experimental model α-MSH did not reduce renal inflammation and did not improve 
short-term graft function following DBD kidney transplantation.
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Introduction
Kidneys of deceased brain dead (DBD) donors are the main source of kidneys for 
transplantation world-wide. In 2012, 64% of all renal transplants in Europe were from 
DBD donors1. Despite significant advances in recipient management, delayed graft 
function (DGF) and primary non-function (PNF) remain as serious complications of DBD 
donor renal transplantation occurring in 18 - 28 % and 2 - 4 % of recipients respectively2–4. 
DGF is associated with additional burden to the patient and with increased rejection risk, 
reduced graft survival and higher costs associated with extended hospital admission. 
Thus, outcome from DBD donation remains inferior to living donation. Preventing injury 
to the DBD kidney allograft may improve short-term kidney function and also influence 
longer term graft survival.
Brain death induces a systemic, inflammatory state. This is caused by hemodynamic 
changes and neuronal injury. Cytokines such as IL-6 and MCP-1 mediate leukocyte 
infiltration that occurs alongside systemic complement system activation5–8. This 
systemic response results in inflammatory activation of the donor end organ, which is 
increased by hemodynamic instability8. Overall, brain death results in injured organs 
even prior to organ retrieval. This injury is worsened by the additive effects of preservation 
and ischemia/reperfusion (I/R) injury9. As the major part of I/R injury arises during the 
reperfusion phase, renoprotective treatment of recipients is an attractive therapeutic 
option.
α-melanocyte stimulating hormone is a pleiotropic neuropeptide with renoprotective 
capacities demonstrated in several models of acute kidney injury including cyclosporine 
induced nephrotoxicity10, ureteral obstruction11 and I/R injury12–17. In renal I/R models 
α-MSH administered up to six hours post-reperfusion improved renal function and 
resulted in reduced acute tubular necrosis and neutrophil influx12. The protective effect 
is not fully dependent on inhibition of neutrophil activation, as α-MSH was still protective 
in renal I/R in ICAM-1 knock-out mice13. In addition, α-MSH prevented the down-
regulation of aquaporins and sodium transporters involved in tubular reabsorbtion of 
water following acute kidney injury11,16.
As DBD donor kidney allografts are affected by the brain death process and I/R injury, 
α-MSH treatment of the recipient may post-condition kidneys to improve short-term 
renal function following transplantation and reduce the incidence of DGF and PNF. We 
therefore hypothesized that α-MSH treatment of the recipient protects against renal 
inflammation and I/R injury in a porcine model of DBD kidney transplantation leading 




Animals and ethics statement:
Twenty-four Danish Landrace pigs (50-65 kg.) were used. The pigs were fasted overnight 
before surgery with free access to water. The animal experiments were performed in 
strict accordance with international and Danish guidelines of animal research. The study 
protocol was approved by the Danish Animal Experiments Inspectorate and included 
moving, sedation and surgery of the animals (permit number: 2012-15-2934-00122). 
All surgery was performed under anesthesia and all efforts were made to minimize 
suffering. Samples size of eight animals per treatment group was calculated based on 
a 2-sided α of 0.05, a power of 0.9 and an effect size of 1.92.
Study design:
To test our hypothesis, we used a randomized, paired design. Eight pigs were used 
as DBD donors and both kidneys were transplanted. After four hours of brain death 
both kidneys were removed and cold storage lasted nineteen hours. Donor kidneys 
derived from the same donor were transplanted simultaneously to one α-MSH- and one 
vehicle treated recipient. The follow-up was ten hours following reperfusion. The study 
was investigator-blinded and recipients were randomized in a paired design into two 
treatment groups. Surgeons and right- and left kidneys were also randomized into the 
two treatment groups. α-MSH (Bachem, Bubendorf, Switzerland) was dosed at 200 µg/
kg and saline (0,9%) served as vehicle treatment. 200 µg/kg was chosen based on its 
protective effect against renal I/R injury as shown by Gong et al. and Simmons et al.16,17. 
Both treatments (0.2 ml/kg) were infused over ten minutes. Administration was started 
five minutes prior to start of abdominal surgery, five minutes prior to reperfusion and 
two hours post-reperfusion. The study design is shown in figure 1.
Figure 1 - Study design. Abbreviations: brain death (BD), cold storage (CS), transplantation (Tx).
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Anesthesia and monitoring
Before transport to the animal operation facility, pigs were sedated by intramuscular 
injections of azaperone (0.1 ml/kg) and midazolam (0.5 mg/kg). At arrival midazolam 
(0.5 mg/kg), ketamine (5 mg/kg) and atropine (0.01 mg/kg) was given to prolong 
sedation. Prior to intubation midazolam (0.5 mg/kg) and ketamine (5 mg/kg) was 
administered intravenously. After intubation continuous anesthesia was maintained 
using propofol (8 mg/kg/hr) and fentanyl (25 µg/kg/hr). Animals were ventilated with 
40% oxygen and a tidal volume of 10 ml/kg. Expiratory CO2 was controlled between 
4.5- and 5.5 kPA by adjusting respiratory rate. Ringer acetate was infused continuously 
(donors: 10 ml/kg/hr; recipients: 15 ml/kg/hr). The carotid artery and jugular vein were 
catheterized. Blood pressure was monitored via a pressure catheter in the carotid artery. 
Mean arterial pressure (MAP) was maintained above 60 mmHg. If MAP decreased 
below 60 mmHg a bolus infusion of one liter Ringer’s acetate was given and if not 
sufficient to maintain MAP above 60 mmHg an intravenous bolus of adrenalin (0.05 
mg) was administered. Cefuroxime (750 mg) was administered as antibiotic treatment 
before start of surgery and repeated after six hours. A bolus of 20 ml 50% glucose was 
administered if the blood glucose level dropped below 4.0 mmol/l.
Deceased brain dead kidney donation
For brain dead induction two holes were drilled in the cranium. Intracranial pressure 
was measured through the first hole and via the secondary hole a 22Fr 60cc Foley 
urine catheter was inserted in the epidural space. Brain death was induced by inflating 
the balloon of the 22Fr 60cc Foley urine catheter with saline at a rate of 1ml/min. 
The exact time of brain death was determined when intracranial pressure was higher 
than the mean arterial pressure18,19. At this point ten ml extra saline was infused in the 
intracranial catheter (1ml/min) to ensure no circulation of the brain. To prevent muscle 
cramps rocuronium (130 mg) was administered intravenously. Continuous propofol 
administration was stopped after declaration of brain death. After four hours of brain 
death, donor surgery was started by midline laparotomy. Both kidneys were dissected. 
Prior to removal of the kidneys heparin (20000 IU) was given and kidneys were flushed 
in situ with one liter of 4°C Custodiol®. After donation kidneys were preserved at 4°C 
for 19 hours.
Transplantation
The transplantation procedure in recipients was started by a midline incision and 
both kidneys were approached retroperitoneally. Right- and left nephrectomy was 
performed and donor kidneys were transplanted by end-to-end anastomoses to the left 
renal artery and vein. During surgery the organs were cooled with frozen glucose. The 
ureter was catheterized with a 10Fr feeding tube. Fifteen minutes post-reperfusion the 
abdomen was closed. After ten hours of follow-up the recipients were sacrificed using 




Blood and urine samples were taken via a carotid artery catheter and catheterized 
ureters, respectively. Blood and urine samples of the recipient were obtained at the 
moment of reperfusion, each 30 minutes in the first 2 hours and then hourly till end of 
follow-up.
Blood and urine samples were stored at -80°C. Cortical and medullary samples 
of the kidney were snap frozen in liquid N2 and stored at -80°C for qRT-PCR. For 
immunohistochemistry kidney tissue samples were fixated in 4% formalin and 
subsequently embedded in paraffin. Aldosterone was measured in plasma using Coat-
A-Count® kit (TKAL2, Siemens, Malvern, USA) according to manufacturer’s instructions.
Glomerular	filtration	rate
The primary endpoint of the study was renal function defined as GFR measuring 51Cr-
EDTA clearance. An intravenous bolus of 51Cr-EDTA (2.6 mBq) was administered followed 
by continuous infusion of 51Cr-EDTA (1.3 mBq/hour). The activity in blood and urine 
samples was counted using a gamma ray detector (Cobra II, Packard, Meriden, CT). 
Values were corrected for decay. The GFR was calculated using the following formula:  
GFR = (urinary 51Cr-EDTA (CPM/ml) * urine flow (ml/min)) / plasma 51Cr-EDTA (CPM/
ml).
Quantitative real-time reverse transcription polymerase chain reaction 
(qRT-PCR)
RNA was extracted from snap frozen tissue using Trizol reagent according to the 
manufacturer’s instructions (Invitrogen, Breda, the Netherlands). Total RNA was 
treated with DNAse I to remove genomic DNA contamination (Invitrogen, Breda, the 
Netherlands). The integrity of total RNA was analyzed by gel electrophoresis. cDNA 
was synthesized from 1-μg total RNA using M-MLV (Moloney murine leukaemia virus) 
Reverse Transcriptase and oligo-dT primers (Invitrogen, Breda, The Netherlands). 
Primer sets were designed using Primer Express 2.0 software (Applied Biosystems, 
Foster City, CA). Amplification and detection were performed with the ABI Prism 7900-
HT Sequence Detection System (Applied Biosystems) using emission from SYBR green 
master mix (Applied Biosystems). The PCR reactions were performed in triplicate. After 
an initial activation step at 50°C for 2 min and a hot start at 95°C for 10 min, PCR 
cycles consisted of 40 cycles at 95°C for 15 sec and 60°C for 60 sec. Dissociation 
curve analysis were performed for each reaction to ensure amplification of specific 
products. 
Genes and primers are shown in table 1. Gene expression was normalized with the 
mean of 18S mRNA content and calculated relative to controls or contralateral kidneys. 
Results were finally expressed as 2–ΔCT (CT threshold cycle), which is an index of the 
relative amount of mRNA expression in each tissue.
45
3
α-melanocyte stimulating hormone in DBD kidney transplantation
Immunohistochemistry
Three-μm-thick sections were cut from paraffin embedded kidney tissue. For 
evaluation of renal morphology sections were stained by Periodic Acid-Schiff (PAS). 
For immunohistochemical aquaporin-2 (AQP-2) staining sections were deparaffinized 
and endogenous peroxidase was blocked by incubation with 3.5% H2O2 for 30 
minutes. Antigens were retrieved by boiling sections for 15 minutes in Tris/EGTA buffer 
(pH 9.0). Endogenous biotin was blocked using a ready-to-use blocking kit (X0590, 
DAKO, Glostrup, Denmark). Unspecific binding of free aldehyde groups was blocked 
by 30 minutes incubation in 50 mM NH4Cl followed by blocking of unspecific antibody 
binding by 30 minutes incubation in 1%BSA, 0,2 % gelatin and 0,05% saponin. The 
primary antibody (Anti-AQP2, 1:500, 7661AP) was incubated overnight followed by 
incubation with a secondary peroxidase-conjungated goat-anti-rabbit antibody (1:300, 
DAKO, Glostrup, Denmark). Sensitivity was increased and background was reduced by 
the ready-to-use ABC Kit (PK 4000, Vectastain, Vector). Then the peroxidase activity 
was visualized by ten minutes incubation in 3.3-diaminobenzidine tetrachloride. 
Subsequently the sections were counterstained with hematoxylin.
Finally, the sections were scanned using APERIO scanscope (Aperio, Vista, United 
States). The intensity of the immunohistochemical staining of each section was 
quantified using APERIO image scope software.
Table 1 - qRT-PCR primers
Gene Forward Reverse Amplicon 
lenght (bp)
18S AGTCCCTGCCCTTTGTACACAC AACCATCCAATCGGTAGTAGCG 51
IL-1β GATGACACGCCCACCCTG CAAATCGCTTCTCCATGTCCC 75
IL-6 AGACAAAGCCACCACCCCTAA CTCGTTCTGTGACTGCAGCTTATC 69
IL-10 AGTGTGACAAAGTCGCTTACACTCA AGGGCCACCGGAATATTAGCT 75
TNF-α GGCTGCCTTGGTTCAGATGT CAGGTGGGAGCAACCTACAGTT 63
MCP-1 ACTTGGGCACATTGCTTTCCT TTTTGTGTTCACCATCCTTGCA 84
ICAM-1 GGCTGTGCACTGCAACAAGA TGTGGCAATGCCAAATCCT 75
Na-K ATPase AGAGGAAGATCGTGGAGTTCACC AATTCCTCCGGGTCTTGCAG 75
AQP-1 GAAGGCTGGATTCTATCTACATAAGTCC TTGTCTAGCTGAAACCGTGGG 86
AQP-2 CTGTGGAGCTTTTCCTGACC TAGTGGATCCCGAGAAGGTG 100
AQP-3 CTCATGGTGGTTTCCTCACC CAAGGATACCCAGGGTGACA 24
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Urinary markers of acute kidney injury
Neutrophil gelatinase-associated lipocalin (NGAL) was measured using a NGAL ELISA 
kit (Bioporto diagnostics A/S, Gentofte, Denmark). N-acetyl-b-D-glucosaminidase (NAG) 
was measured by a modified enzyme assay at pH 4.25 using p-nitrophenyl-N-acetyl-b-D-
glucosaminide as substrate (Sigma-Aldrich, Zwijndrecht, the Netherlands). The activity 
of alanine aminopeptidase (AAP) was detected with the modified enzymatic assay 
using alanine-p-nitroanilide (Sigma-Aldrich, Zwijndrecht, the Netherlands).
Statistical analyses
Grouped and paired data was analyzed using the repeated measurement ANOVA and 
is presented as mean±standard error of the mean (SEM). Data on specific times has 
been analyzed using Wilcoxon signed rank test or Man Whitney U test depending on 
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Figures	3:	Effect	of	α-MSH	on	GFR.	Figure A shows the recovery of renal function during follow-up of ten 
hours. At ten hours post-reperfusion α-MSH significantly reduced GFR (B; * = p<0.05). 
Results
Effect on clinical parameters
During ten hours follow-up urine output was significantly lower in the α-MSH group 
compared to controls (Figure 2, p<0.05). None of the controls or α-MSH treated animals 
were anuric. 
Figure	2	-	Effect	of	α-MSH	on	urine	
flow.	 Urine flow was significantly 
lower in the α-MSH group compared 
to controls during ten hours follow-up.
α-MSH treatment tended to impair recovery of GFR (Figure 3A) during ten hours follow-
up compared to controls. At ten hours post-reperfusion, GFR of α-MSH treated animals 
was significantly lower compared to controls (Figure 3B; 8.2±5.7-13.3 ml/min vs. 
14.3±10.1-19 ml/min; p<0.05). 
Sodium excretion was also reduced by α-MSH treatment at ten hours post-reperfusion 
compared to controls (Figure 4; 2.8±1.2-4.5 mmol/min vs. 5.4±4.2-5.8 mmol/min; 
p<0.05). Plasma creatinine and urea levels increased during follow-up in both groups, 




During surgery heart rate of all animals increased. After reperfusion, heart rate 
decreased to baseline levels in both groups. Each dose of α-MSH tended to increase 
heart rate by 10 beats per minute (BPM) (Figure 5A). Mean arterial pressure (MAP) 
increased during surgery. After reperfusion, MAP decreased to baseline levels during the 
ten hour follow-up. Each dose of α-MSH tended to decrease MAP by approximately 10 
mmHg. After the first two doses this appeared within the first hour after administration 
and after the third dose this was observed in the second hour after administration 
(Figure 5B). One α-MSH treated animal required a bolus of one liter Ringer’s acetate 
and adrenalin (0.025 mg) five minutes post-reperfusion because of rapidly decreasing 
MAP to levels below 35 mmHg. The recipient stabilized immediately after one dose of 
adrenalin and one liter Ringer’s acetate. None of the control animals required adrenalin 
treatment. During ten hours follow-up one α-MSH treated animal required two boluses 
of one liter Ringer’s acetate to maintain MAP above 60 mmHg while in none of the 
controls MAP dropped below 60 mmHg. 
Figure	4	-	Effect	of	α-MSH	on	sodium	
excretion. Sodium excretion per minute 
was reduced by α-MSH (* = p<0.05). 
Figure	5	-	Effect	of	α-MSH	on	hemodynamic	parameters. α-MSH tended to increase heart rate (A) and 
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The need for glucose supplementation to maintain blood glucose levels above 4.0 
mmol/l was significantly lower in α-MSH treated animals (Figure 6A; 0±0-20 ml 50% 
glucose vs. 40±0-60 50% glucose; p<0.05). Despite more glucose supplementation 
blood glucose levels of controls tended to be lower compared to α-MSH treated animals 
(Figure 6B). 
One control- and one α-MSH treated recipient transplanted simultaneously were excluded 
from these analyses because of an excessive need for glucose supplementation, 420 
and 200 ml 50% glucose, respectively. 
Hemoglobin levels decreased during surgery and ten hours follow-up. α-MSH treatment 
did not affect hemoglobin levels compared to controls (Supplemental data – Figure 
2A). No differences in blood pH or lactate levels were observed between α-MSH 
treatment and controls (Supplemental data– Figure 2B and 2C). α-MSH treatment 
did not influence ASAT or ALAT levels (Supplemental data – Figure 3A and 3B). LDH 
levels decreased in the control group during follow-up, while such change was not seen 
in the α-MSH group at ten hours post-reperfusion (Figure 7A, p<0.05). Thirty minutes 
post-reperfusion α-MSH treatment increased plasma aldosterone levels significantly 
compared to the controls (Figure 7B, 104±61-115 pg/ml vs. 29±29-44 pg/ml; p<0.05). 
Figure	6	-	Effect	of	α-MSH	on	glucose	levels.	α-MSH significantly reduced the need of glucose treatment 
(A; * = p<0.05) and tended to prevent a decrease of blood glucose levels (B).
A B
BA
Figure	7	-	Effect	of	α-MSH	on	LDH	and	aldosteron.	Ten hours post-reperfusion LDH was higher in α-MSH 
treated animals compared to controls (A* = p<0.05). Thirty minutes post-reperfusion α-MSH treatment 
increased plasma aldosteron levels (B, * = p<0.05).
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Effect on urinary markers of acute kidney injury
Urinary excretion of renal injury markers, respectively NGAL, NAG and AAP, was highest 
in the first 30 minutes post-reperfusion. NGAL excretion did not differ between α-MSH 
treated animals and controls (Figure 8A). However, α-MSH treatment significantly 
reduced AAP and NAG excretion rate during follow-up. The difference is based on a 
significant reduction in the first thirty minutes (Figure 8B and 8C; p<0.05). 
Effect	on	inflammation
The effect of α-MSH on inflammatory markers was measured in cortical tissue collected 
at ten hours post-reperfusion (Figure 10). Expression of interleukin-1β (IL-1β), -6 (IL-
6) or -10 (IL-10) was not significantly affected by α-MSH treatment. No differences 
were observed in mRNA levels of intercellular adhesion molecule-1 (ICAM-1), tumour 
necrosis factor-α (TNF-α) or monocyte chemoattractant protein-1 (MCP-1).
Figure	9	-	Effect	of	α-MSH	on	inflammatory	markers.	α-MSH treatment did not significantly affect 
mRNA expression of IL-1β, IL-6, IL-10, ICAM-1, TNF-α or MCP-1.
Figure	8	-	Effect	of	α-MSH	on	urinary	markers	of	acute	renal	injury.	α-MSH significantly reduced AAP 
and NAG excretion in the first thirty minutes (* = p<0.05).
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Figure	10:	 The	effect	of	α-MSH	on	aquaporins	and	Na-K	ATPase.	No significant differences were 
observed in mRNA expression of aquaporines or Na-K ATPase mRNA expression between controls and 
α-MSH treated animals at ten hours post-reperfusion.
Effect on renal morphology and aquaporins
No differences were observed in renal morphology between α-MSH treated animals and 
controls. In addition to morphological changes we investigated the effect of α-MSH on 
renal expression of aquaporins and Na-K ATPase. At ten hours post-reperfusion cortical 
mRNA expression levels of aquaporin-1 (AQP-1), -2 (AQP-2), -3 (AQP-3) and Na-K ATPase 
were not significantly affected by α-MSH treatment (Figure 10). However, quantification 
of immunohistochemical staining showed increased cortical AQP-2 protein expression 
following α-MSH treatment indicative of increased AQP-2 activity in the renal cortex 
(Figure 11 A-D; 0.6±0.3-0.7 vs. 0.2±0.1-0.3; p<0.05).
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Figure	 11:	 The	 effect	 of	 α-MSH	 on	 AQP-2	 protein	 expression.	 Figure A and B show sections of 
medullary and cortical AQP-2 staining, respectively. No differences were observed in medullary AQP-2 
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Discussion
This study was designed to test the hypothesis that α-MSH treatment of recipients of a 
DBD donor kidney improves early graft function and reduces inflammation. Surprisingly, 
α-MSH treatment impaired recovery of GFR following DBD transplantation. Furthermore, 
no anti-inflammatory capacities of α-MSH were observed after ten hours follow-up. 
Urinary excretion of markers of acute kidney injury, AAP and NAG, were reduced by 
α-MSH treatment, but only in the first 30 minutes post-reperfusion and urinary NGAL 
excretion was not affected. Besides, α-MSH administration was associated with a 
slightly increased AQP-2 protein expression in renal cortex.  However, it is uncertain 
whether these small changes in urinary markers of acute kidney injury and aquaporin 
expression are clinically relevant. 
α-MSH impaired GFR recovery after DBD kidney transplantation. This may be explained 
by changes in hemodynamics following each dose of α-MSH. Heart rate increased 
by approximately ten beats per minute in the hour following α-MSH administration, 
while α-MSH administration was associated with 10 mmHg reduction of MAP. In 
the literature, the effects of α-MSH on hemodynamics are variable. In particular the 
hemodynamic effect of intravenous administration of α-MSH is debatable and mainly 
based on studies in rodents20–23. However, in sheep α-MSH (75 µg/kg) decreased MAP, 
while heart rate and aortic flow increased directly following treatment suggesting a 
decrease of systemic vascular resistance. Blood flow to lungs and heart increased, but 
renal blood flow was not significantly affected24. 
In this study, 200 µg/kg α-MSH was used, which was chosen based on the previously 
shown protective effect against renal I/R injury16,17. Gong et al. demonstrated the 
protective effect of α-MSH in renal I/R injury in rats16,17. Furthermore, Simmons et 
al. tested the protective effects of 200 µg/kg AP214, which is a synthetic analogue 
of α-MSH with 6 lysine residues added to its amino terminus, in renal I/R in pigs16,17. 
However, in both the rodent- and porcine I/R model the effect of α-MSH or AP214 on 
hemodynamics was not investigated. It was therefore unexpected that α-MSH seemed 
to directly affect hemodynamics. Possibly, the hemodynamic changes counteracted the 
proposed renoprotective effect of α-MSH.
Recently, it has been shown that α-MSH is able to induce vasodilatation by endothelial 
derived nitric oxide (NO) via activation of melanocyte receptor-1 (MCR-1)25. Based 
on this mechanism, one could speculate that α-MSH might increase GFR due to the 
expression of MCR1 in renal glomeruli26. However, we did not observe this in our model. 
A potential stimulative effect of α-MSH on GFR might be counteracted by systemic 
vasodilatation and subsequent decreased MAP. Plasma aldosterone levels increased 
to stabilize hemodynamics after administration of α-MSH, indicating activation of the 
renin angiotensin aldosterone system (RAAS). 
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Activation of the RAAS system causes increased sodium retention and renal 
vasoconstriction27. In renal I/R, inhibition of the RAAS system improves renal function, 
reduces inflammation and prevents structural injury28. This suggests activation of the 
RAAS system following renal I/R injury is detrimental. Therefore, activation of the 
RAAS system due to hemodynamic instability following α-MSH administration probably 
caused the impaired GFR in this model. 
The follow-up of ten hours after transplantation is relatively short, which is a limitation. 
Based on the protective effect of α-MSH against acute kidney injury, the short follow-up 
was chosen specifically to study the effects of α-MSH on immediate graft function and 
acute inflammation following DBD transplantation12–17. The effect of α-MSH on long-
term renal function after transplantation and structural injury was not investigated and 
cannot be deducted from our present results. However, α-MSH impaired recovery of 
GFR and failed to show any reduction of inflammatory qRT-PCR markers. We believe 
it is rather unlikely that the short follow-up period masked the capacity of α-MSH to 
improve early graft function following DBD transplantation.  
α-MSH can bind to four different melanocortin receptors (MCR1, MCR3, MCR4, MCR5). 
These different receptors are responsible for pleiotropic function of α-MSH, like regulation 
of pigmentation, hemodynamics, glucose metabolism and immunomodulation28,29. 
The anti-inflammatory effect is mainly mediated by MCR1, but also by MCR3 and 
MCR4. The anti-inflammatory capacities of α-MSH are based on modulation of antigen 
presenting cells and reduced production of cytokines such as IL-1β, TNF-α and IL-628,30,31. 
Although MCR1 and MCR3 expression in the kidney is slightly decreased after renal 
I/R, renal expression of these receptors suggests α-MSH treatment might be locally 
protective28,32. Chiao et al. showed using isolated perfused kidneys after renal ischemia 
that addition of α-MSH to the perfusion solution improves renal function indicating that 
α-MSH mediated renoprotection is based on a renal binding to MCR’s13. In our study, 
no differences in cortical expression of several markers of inflammation was found 
between controls and α-MSH treated animals. The local anti-inflammatory effects, as 
shown in models of acute kidney injury10,12,15, might be counteracted by systemic effects 
of MCR1,3-5. The hemodynamic effects and the effect on blood glucose levels suggest 
systemic activity of α-MSH in this porcine transplantation model. Selective agonists 
of MCR1, MCR3 or MCR4 might induce anti-inflammatory effects without possible 
adverse effects of activating the complete MCR system. 
Renal I/R injury results in down-regulation of aquaporins and sodium transporters29,33. 
Aquaporins and sodium transporters are important for the renal reabsorptive capacity 
of water and sodium. In models of acute kidney injury, prevention of down-regulation 
of aquaporins and sodium transporters is associated with reduced sodium and water 
excretion and improved renal function11,14,16,34. 
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In this study α-MSH seemed to slightly increased cortical AQP-2 protein expression. 
Clinically, urine flow was halved and sodium excretion reduced, but recovery of GFR 
was impaired. These functional renal effects are presumably caused by changes in 
hemodynamics and not by the small changes in AQP-2 expression. 
The anti-inflammatory effects and improvement of renal function observed after α-MSH 
treatment in various models of acute renal injury suggested α-MSH could prevent DGF 
and PNF following DBD kidney transplantation. However, α-MSH seemed to reduce MAP 
and impaired short-term recovery of renal function. Anti-inflammatory capacities of 
α-MSH were not observed. In conclusion, α-MSH treatment of recipients did not improve 
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Supplemental	data	-	Figure	3:	Effect	of	α-MSH	on	plasma	ASAT	and	ALAT	levels.
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